Is mirtazapine effective for treating extrapyramidal symptoms (EPS) such as acute dystonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mirtazapine Does Not Treat EPS Symptoms

Mirtazapine is not a treatment for extrapyramidal symptoms (EPS) such as acute dystonia. In fact, mirtazapine itself can paradoxically cause movement disorders, though it may attenuate antipsychotic-induced EPS in specific experimental contexts.

Evidence-Based Treatment for EPS

Acute Dystonia

For acute dystonic reactions (sudden spastic muscle contractions affecting neck, eyes, or torso), anticholinergic or antihistaminic medications are the established first-line treatments 1, 2. These reactions can be life-threatening (e.g., laryngospasm) and require immediate intervention with agents like benztropine or diphenhydramine.

Drug-Induced Parkinsonism

Treatment options include 2:

  • Lowering the antipsychotic dose
  • Switching to another antipsychotic medication
  • Adding an anticholinergic medication or amantadine

Akathisia

Management strategies include 2:

  • Lowering the antipsychotic dose (if clinically feasible)
  • Switching to another antipsychotic
  • Adding a benzodiazepine
  • Adding a beta-adrenergic blocking agent

Important Caveats About Mirtazapine

Mirtazapine can actually cause movement disorders itself, not treat them 3. A comprehensive literature review identified 179 cases of mirtazapine-associated movement disorders, including restless legs syndrome, tremors, akathisia, dystonia, and parkinsonism. These typically occurred within 7.54 days of starting mirtazapine, with management requiring drug withdrawal in most cases 3.

Experimental Context Only

While one preclinical study showed mirtazapine attenuated haloperidol-induced bradykinesia and catalepsy in rodents 4, this does not translate to clinical practice. The study suggested mirtazapine's noradrenergic and specific serotonergic antidepressant (NaSSA) properties might be superior to SSRIs when combining antidepressants with antipsychotics, but this relates to preventing EPS augmentation, not treating established EPS.

Risk of Serotonergic Antidepressants

Serotonergic antidepressants, including mirtazapine, have been associated with extrapyramidal reactions since 1958 5. These reactions typically occur within 30 days of treatment initiation or dose increase and can include akathisia, dystonia, dyskinesia, and parkinsonism.

Clinical Bottom Line

Use established EPS treatments: anticholinergics for acute dystonia, dose reduction or anticholinergics for parkinsonism, and beta-blockers or benzodiazepines for akathisia 1, 2. Mirtazapine has no role in treating EPS and may itself cause movement disorders requiring discontinuation 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.